Treatment of epilepsy in the multiply handicapped.
The medical management of epilepsy in the multi-handicapped patient requires careful evaluation, classification, and pharmacologic treatment. It is estimated that 20-40% of patients with mental retardation and cerebral palsy have epilepsy. This review reports the clinical trial data and personal experience related to the use of newer AEDs in the chronic management of epilepsy syndromes in children and adults, as well as information available on the treatment of seizures in individuals with mental retardation and associated handicaps. Furthermore, clusters of seizures, prolonged seizures and status epilepticus are more commonly seen in the multiply handicapped and mentally retarded population and require special attention. The new antiepileptic drugs felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin and zonisamide show specific advantage in some multiply handicapped patients, be it for seizure control or medication tolerance. Furthermore, new modalities of treatment for prolonged seizures allow better efficacy both outside of hospital and within hospital facilities. The treatment of epilepsy in multi-handicapped and retarded adults and children has significantly advanced in the past few years, and much of this improvement can be attributed to improved knowledge and monitoring of new antiepileptic drugs. Conventional anticonvulsants remain first line therapy for most clinicians, but newer AEDs must broaden the therapeutic option and do allow improved therapy for some multiply handicapped patients.
Pellock
J M
JM
Division of Child Neurology, Department of Neurology, Pediatrics, Pharmacy, and Pharmaceutics, MCV Hospitals and Physicians, Virginia Commonwealth University Health System, Richmond, Virginia 23289, USA.
Morton
L D
LD
D000927:Anticonvulsants / Q000008:administration & dosage* / Q000009:adverse effects; D006233:Persons with Disabilities / Q000534:rehabilitation*; D004827:Epilepsy / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans
D000927:Anticonvulsants